KDIGO 2025儿童肾病综合征管理临床实践指南执行摘要
KDIGO 2025儿童肾病综合征管理指南是对2021年肾小球疾病指南的更新,提供了肾活检和/或基因检测时机的治疗算法,以及激素敏感、频复发、激素依赖患儿的免疫抑制治疗选择。当初始激素治疗未能诱导缓解时,选择钙调神经磷酸酶抑制剂、口服环磷酰胺、左旋咪唑、吗替麦考酚酯或利妥昔单抗需考虑资源、依从性、不良反应和患者偏好。
要点
- 更新指南提供了儿童肾病综合征肾活检和/或基因检测时机的治疗算法。
- 激素敏感后转为频复发或激素依赖的患儿,指南明确了免疫抑制治疗选择。
- 初始激素治疗失败时,选择激素节约剂需个体化考虑资源、依从性、不良反应和偏好。
核心结论
- KDIGO 2025儿童肾病综合征指南更新了肾活检和/或基因检测时机及免疫抑制治疗选择。
研究设计与样本
- KDIGO基于2021年肾小球疾病指南的定期更新,针对儿童肾病综合征制定临床实践指南。
主要发现
- 更新指南包含肾活检和/或基因检测时机的治疗算法。
- 对激素敏感后转为频复发或激素依赖的患儿,指南提供了免疫抑制治疗选择。
- 初始激素治疗未能诱导缓解时,钙调神经磷酸酶抑制剂、口服环磷酰胺、左旋咪唑、吗替麦考酚酯和利妥昔单抗的选择需考虑资源、依从性、不良反应和患者偏好。
临床怎么用
- 临床可参考更新指南的治疗算法决定肾活检和/或基因检测时机。
- 对激素敏感后频复发或激素依赖的患儿,按指南选择免疫抑制治疗方案。
- 初始激素治疗失败时,个体化选择激素节约剂需综合评估资源、依从性、不良反应和患者偏好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases was last updated and published in 2021. KDIGO continues to be committed to the nephrology community to provide periodic updates, based on new developments for each of the glomerular diseases. For children with nephrotic syndrome, the updated guideline now contains a treatment algorithm on when to perform a kidney biopsy and/or genetic testing and which immunosuppressive therapy to use in children with a complete response to glucocorticoids (steroid sensitive), who subsequently become infrequent or frequent relapsers or even steroid dependent. If a glucocorticoid-sparing agent must be considered after failure of an initial glucocorticoid therapy to induce remission, the choice among a calcineurin inhibitor, oral cyclophosphamide, levamisole, mycophenolate mofetil, and rituximab is a decision that requires consideration of patient-related issues such as resources, adherence, adverse effects, and patient preferences. Herein, an executive summary of the most important changes in the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children is provided as a quick reference.
引用
- Floege J, Gibson KL, Vivarelli M, et al. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Kidney Int. 2025. PMID: 40254362. doi:10.1016/j.kint.2024.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。